Abstract
In 2003, two inhibitors of phosphodiesterase 5 (PDE5) — tadalafil (Cialis; Lilly ICOS) and vardenafil hydrochloride (Levitra; Bayer/ GlaxoSmithKline) — were approved by the US FDA for the treatment of erectile dysfunction. Can they challenge the dominance of the first PDE5 inhibitor, sildenafil citrate (Viagra; Pfizer), which rapidly became a blockbuster following its market entry in the late 1990s?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lue, T. F. Erectile dysfunction. N. Engl. J. Med. 342, 1802–1813 (2000).
NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 270, 83–90 (1993).
Rotella, D. P. Phosphodiesterase 5 inhibitors: current status and potential applications. Nature Rev. Drug Disc. 1, 674–682 (2002).
Terrett, N. K. et al. Sildenafil (Viagra), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg. Med. Chem. Lett. 6, 1819–1824 (1996).
Daugan, A. et al. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1:5,6,11,11a-tetrahydro-1H-imidazo[1′,5′:1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues. J. Med. Chem. 46, 4525–4532 (2003).
Daugan, A. et al. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione analogues. J. Med. Chem. 46, 4533–4542 (2003).
Haning, H. et al. Imidazo[5,1-f][1,2,4]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors. Bioorg. Med. Chem. Lett. 12, 865–868 (2002).
FDA Drug Approvals List [online], (cited 10 Feb 2004), <http://www.fda.gov/cder/foi/label/2003/021368lbl.pdf> (2003).
FDA Drug Approvals List [online], (cited 10 Feb 2004), <http://www.fda.gov/cder/foi/label/2003/021400lbl.pdf> (2003).
Rajfer, J. et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N. Engl. J. Med. 326, 90–94 (1992).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Neumeyer, K., Kirkpatrick, P. Tadalafil and vardenafil. Nat Rev Drug Discov 3, 295–296 (2004). https://doi.org/10.1038/nrd1362
Issue Date:
DOI: https://doi.org/10.1038/nrd1362
